Pure Global
NCT02869295

A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors

An Open-Label, Multicenter, Dose Escalation And Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumor Malignancies
Nektar Therapeutics·Early Phase 1·ClinicalTrials.gov·drugCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Unspecified Adult Solid Tumor, Protocol Specific
Drug/Device/Intervention
NKTR-214
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Nektar Therapeutics
Location
New Haven,Portland,Houston, United States of America
Timeline & enrollment
Phase
Early Phase 1
Start date
Dec 01, 2015
End date
Oct 31, 2018
Enrollment
28 participants
Primary outcome

Safety of NKTR-214 as Evaluated by Incidence of Drug-related Adverse Events (AEs),Tolerability of NKTR-214 as Evaluated by Incidence of Dose Limiting Toxicities (DLTs)

Summary

This is a first in human, open-label, sequential dose escalation and expansion Phase 1 study
 of NKTR-214 in adult patients with locally advanced or metastatic solid tumors.

ICD-10 classifications
Carcinoma in situ, unspecifiedMalignant neoplasm, without specification of siteMalignant neoplasm, primary site unspecifiedCarcinoma in situ of other and unspecified genital organsMalignant neoplasm: Connective and soft tissue, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT02869295
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT02869295 through Pure Global AI's free database. This Early Phase 1 trial is sponsored by Nektar Therapeutics and is currently Completed. The study focuses on Unspecified Adult Solid Tumor, Protocol Specific. Target enrollment is 28 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.